Continuing Education Activities
Here at JADPRO CE, you can find a valuable array of certified educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!
Case Study 1: HDMTX-Induced AKI in Osteosarcoma
Using the case of a 31-year-old female patient undergoing treatment for osteosarcoma, Nancy Nix, PharmD, BCPS, BCOP, and Kristi Posey, PA, discuss risk factors for acute kidney injury following high-dose methotrexate (HDMTX) treatment, as well as the importance of pretreatment patient counseling and working as a team to quickly identify and treat delayed HDMTX clearance. They also take a deep dive into the consensus guidelines on the use of glucarpidase rescue and how to correlate clinical findings and lab values to increase the timeliness of treatment decision making.
Posted: 9/10/2019 / Expires: 9/10/2020
Estimated time to complete: 30 minutes
Case Study 2: HDMTX-Induced AKI in CNS Lymphoma
Nancy Nix, PharmD, BCPS, BCOP, and Haleigh Mistry, MS, PA-C, discuss the case of a 58-year-old female patient receiving high-dose methotrexate (HDMTX) as part of treatment for central nervous system lymphoma. Together, they review contraindications to HDMTX; the importance of adequate hydration and urine alkalinization prior to initiating therapy; the mechanisms of action of MTX, glucarpidase, and leucovorin; as well as recent studies demonstrating improved outcomes, decreased mortality, and shorter length of hospital stay among patients receiving glucarpidase for HDMTX-induced acute kidney injury.
Posted: 9/10/2019 / Expires: 9/10/2020
Estimated time to complete: 30 minutes
Disease Overview Followed by Selecting Treatments Using Biomarker Testing and Molecular Profiling
Review of strategies for planning therapy based on results of biomarker tests, liquid biopsies, as well as next-generation sequencing and tumor mutational burden profiles.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.75
Managing Early-Stage and Locally Advanced NSCLC
Discussion of evidence-based management of disease using a multimodal approach that includes surgery, adjuvant chemotherapy, chemoradiation, and immunotherapy.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.75
The Role of Immune Checkpoint Inhibitors With and Without Combination Therapy for Nonmutated Metastatic NSCLC
Analysis of therapeutic approaches using immune checkpoint inhibitors alone or with other agents in first-line setting and beyond.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 1.0
Managing Immune-Related Adverse Events
Review of clinical and patient education strategies for identifying, mitigating, and addressing adverse events associated with immune checkpoint inhibitors.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.75
Managing EGFR+ Metastatic NSCLC
Overview of the rationale for targeting EGFR-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of EGFR inhibitors in the first-line setting and beyond.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.5
Managing ALK+ and ROS1+ Metastatic NSCLC
Description Overview of the rationale for targeting ALK- and ROS1-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of ALK inhibitors in the first-line setting and beyond.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.50
Managing Patients With Other Mutations in Metastatic NSCLC and Upcoming Clinical Trials
Evaluation of the rationale for and clinical data supporting targeting driver mutations in NSCLC, such as BRAF, KRAS, and RET. Appraisal of clinical trials planned or in progress in lung cancer for which preliminary or updated data release has occurred in the past 12 months or is expected in the next 6 months. Discussion of new approvals for small cell lung cancer.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.75
Identifying and Avoiding Drug Interactions
Discussion of best practices for mitigating drug-drug interactions and drug-disease interactions.
Posted: 12/10/2019 / Expires: 12/10/2020
Estimated time to complete: 0.50
Consult the Experts: Case Challenges From Conference Participants
Discussion of clinical decision points involved in challenging patient cases, with a focus on how patient disease characteristics and personal preferences can be used to guide clinical decision-making.
Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma
Listen as two multiple myeloma experts break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events, and discover best practices for selecting and sequencing therapy.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Precision Oncology Comes of Age: Tumor-Agnostic Approaches
Guided by two experts in the field, dive into the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support the advancement of precision medicine.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: .75 hour
New Drug Updates: Hematologic Malignancies
Get updated on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 0.75 hours
Addressing the Challenges of Aggressive Lymphomas
Learn how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recommendations, and discovering how to manage associated adverse events in this disease state.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches
Hone your ability to devise first-line treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding clinical data supporting use of targeted and immune checkpoint inhibitor therapies, and managing associated adverse events.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes
Take a deep dive into the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the disease, approved and emerging therapeutics, and strategies for integrating contemporary standard-of-care management practices. Plus, discover best practices for enhancing collaboration and communication within a multidisciplinary, interprofessional team that fosters shared decision-making.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments
Learn from two experts in the field of breast cancer as they discuss the current and future treatment landscape for triple-negative breast cancer, including recent and emerging data on approved treatments, novel therapeutic options being investigated, and best practices for identifying and monitoring adverse events associated with PARP and immune checkpoint inhibitors.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Biomarker BINGO
Test your knowledge on biomarkers and their use in determining targeted therapy for certain tumor types, key assays used to measure common biomarkers, and guideline-endorsed biomarker testing recommendations.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
Current and Future Directions in PARP Inhibition
Review how far PARP inhibition has come and discover where it’s headed, including its potential role in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other factors.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
Recent Advances in the Treatment of Newly Diagnosed Multiple Myeloma
Watch as two experts in the field of multiple myeloma (MM) interpret data on current and novel treatments, discuss how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluate the use of minimal residual disease testing in patients with MM.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment
Review the basic concepts of immunotherapy and the current treatment landscape; explore important aspects of IO care, including the microbiome, provider-patient communication, and survivorship; and evaluate emerging data for ICI-based combinations that are being explored in late-stage clinical trials.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances
Discover the emerging world of chimeric antigen receptor (CAR) T-cell therapy, including the CAR T-cell process, approved indications and studies in hematologic malignancies, strategies for monitoring and managing emerging toxicities, and future directions in the use of this novel therapy.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1 hour
Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
Review data regarding mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL), discover how to devise risk-stratified treatment plans, and learn strategies for managing adverse events associated with approved therapies for CLL.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Improving Outcomes for Patients With Advanced Urothelial Carcinoma of the Bladder
Discover how to select appropriate lines of therapy for treatment of advanced or metastatic urothelial carcinoma and manage associated adverse events in accordance with evidence-based best practices, and learn what’s on the horizon in the treatment of this disease state.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Improving Outcomes in HER2+ Breast Cancer: Analysis and Application of Evolving Data and Best Practices
Through expert, case-based discussion, learn about existing and emerging data for current and investigational therapies for HER2+ breast cancer and their associated adverse events, in addition to best practices for managing central nervous system metastases.
Posted: 2/15/2020 / Expires: 2/14/2021
Estimated time to complete: 1.5 hours
Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
This supplement to JADPRO has been developed in partnership with the AIM With Immunotherapy Immuno-Oncology Essentials group and Terranova Medica. The Appendix includes 12 Care Step Pathways (CSPs), step-by-step guides that are designed to provide comprehensive assessment and management strategies for toxicities unique to immunotherapies. These CSPs work across tumor types, and each of them is discussed in detail in the supplement articles.
This certified activity has expired but you can still participate without claiming credit.
Estimated time to complete: 3 hours
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
The article discusses existing and emerging data in HER2+ breast cancer, effectively managing diarrhea and other adverse events associated with treatments, and implementing best practices for the management of HER2+ breast cancer brain metastases.
This certified activity has expired but you can still participate without claiming credit.
Estimated time to complete: 0.5 hour
Narratives on Collaboration: Optimizing Management of Immune-Related Adverse Events
Learn about best practices for managing irAEs from this interactive JADPRO article, which includes videos, polling, downloadable patient tools and resources, and more.
Posted: July 12, 2019 / Expires: July 12, 2020
Estimated time to complete: 1.0 hour
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy
Despite remarkable promise, CAR T-cell therapies are associated with varied adverse effects, including cytokine release syndrome (CRS), neurotoxicity, and cytopenias. The incidence of CRS has been reported to be as high as 94%. It is imperative that advanced practitioners have the necessary know-how to effectively prevent, treat, and manage CRS related to CAR T-cell therapy.
Posted: November 21, 2019 / Expires: November 21, 2020
Estimated time to complete: 1.0 hour
Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Created by AML experts Nancy Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C, these articles will help you navigate this complex disease, including next-generation sequencing, risk stratification, and use of recently approved therapies, all within the context of interpreting the continually evolving guidelines. The comprehensive Appendix section also lists all of the key information about FDA-approved therapies for AML at a glance.
Posted: December 20, 2019 / Expires: December 19, 2020
Estimated time to complete: 1.0 hour
Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives in Collaboration
Access a full-length article, videos, a Q&A session, and resources on the role of the advanced practitioner in treating patients with myelofibrosis.
Posted: December 20, 2019 / Expires: December 19, 2020
Estimated time to complete: 1.0 hour
Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence
A number of new drugs have been tested and approved for HR+, HER2– breast cancer, including CDK4/6 inhibitors. Oncology has continued to move toward a more patient-specific, precision medicine approach. In the same manner, advanced practitioners have the opportunity to identify patient characteristics, preferences, and needs that are unique to individual patients to enhance precision treatment.
Posted: January 22, 2020 / Expires: January 21, 2021
Estimated time to complete: 1.0 hour